In vivo, treatment with FGF-21 resulted in amelioration of glucose and lipid parameters in both murine and nonhuman primate models of diabetes and obesity [13], [14]. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.